Results 31 to 40 of about 64,427 (282)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate

Iraqi Journal of Hematology, 2020
BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

BMC Cancer, 2010
Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming, Zhou Lin, Yang Yu, Zhu Jiang, Hou Mei   +4 more
doaj   +1 more source

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Asian Pacific Journal of Tropical Biomedicine, 2016
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz, Marjan Khosravani, Sepideh Mohammadi, Hassan Noorbazargan, Amir Mirzaie, Davoud Nouri Inanlou, Mojgan Dalirsaber Jalali, Hamidreza Jouzaghkar, Fahimeh Baghbani-Arani, Behta Keshavarz-Pakseresht   +9 more
doaj   +1 more source

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Jurnal Penyakit Dalam Indonesia, 2020
Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi, Ary Harryanto Reksodiputro   +1 more
doaj   +1 more source

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Turkish Journal of Hematology, 2015
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi   +7 more
doaj   +1 more source

Single-cell epigenomic variability reveals functional cancer heterogeneity. [PDF]

, 2017
BackgroundCell-to-cell heterogeneity is a major driver of cancer evolution, progression, and emergence of drug resistance. Epigenomic variation at the single-cell level can rapidly create cancer heterogeneity but is difficult to detect and assess ...
Buenrostro, Jason D, Chang, Howard Y, Greenleaf, William J, Kathiria, Arwa, Litzenburger, Ulrike M, Sheffield, Nathan C, Shen, Ying, Wu, Beijing   +7 more
core   +2 more sources

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Recent cancer molecular therapies are targeting main functional molecules to control applicable process of cancer cells. Attractive targets are established by receptor tyrosine kinases, such as platelet-derived growth factor receptors (PDGFRs) and c-Kit ...
A. Kadivar, Behnam Kamalidehghan, H. Akbari Javar, B. Karimi, Reihaneh Sedghi, M. I. Noordin   +5 more
semanticscholar   +1 more source